Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, Gill SI, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, Bushman FD, Lacey SF, Tan K, June CH. Nature. Published: 02 February 2022. doi: 10.1038/s41586-021-04390-6
Summary
A new analysis of the first two patients treated in a clinical trial with CAR T cell therapy explains the longest persistence of CAR T cells recorded to date against chronic lymphocytic leukemia and shows that the CAR T cells remained detectable at least a decade after infusion, with sustained remission in both patients. The study, published in Nature, was led by J. Joseph Melenhorst, PhD, a research professor of Pathology and Laboratory Medicine; Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and director of the Center for Cellular Immunotherapies; and David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Cell Therapy and Transplantation at the Abramson Cancer Center. Other Department faculty authors include Drs. Don Siegel and Bruce Levine.
Department news item
Penn Medicine press release
